Vitamin D in cancer chemoprevention

Pharmaceutical Biology

Volumn 53, Issue 10, 2015, Pages 1399-1434

  Giammanco, Marco ^a   Di Majo, Danila ^a   La Guardia, Maurizio ^a   Aiello, Stefania ^a   Crescimannno, Marilena ^a   Flandina, Carla ^a   Tumminello, Francesca M ^a   Leto, Gaetano ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Calcitriol; Cancer prevention; Vitamin D analogues

Indexed keywords

19 NOR 2ALPHA (3 HYDROXYPROPYL) 1ALPHA,25 DIHYDROXYVITAMIN D3; 19 NOR 2BETA (3 HYDROXYPROPYL) 1ALPHA,25 DIHYDROXYVITAMIN D3; 20 EPI 22 ETHOXY 24A,26A,27A TRIHOMO 9,10 SECOCHOLESTA 5,7,10(19) TRIEN 23 YNE 1ALPHA,3BETA,25 TRIOL; 20 EPICALCITRIOL; 22 OXACALCITRIOL; ALFACALCIDOL; BETA CATENIN; BXL 0124; CALCIDIOL 1 MONOOXYGENASE; CALCIPOTRIOL; COLECALCIFEROL 24 HYDROXYLASE; DNA; DOXERCALCIFEROL; ELDECALCITOL; ELOCALCITOL; INECALCITOL; LEXACALCITOL; PARICALCITOL; PROSTAGLANDIN; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; SEOCALCITOL; SOMATOMEDIN; TACALCITOL; TRANSCRIPTION FACTOR FOXO; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE; VITAMIN D RECEPTOR; WNT PROTEIN; ANTINEOPLASTIC AGENT; GROWTH INHIBITOR; IMMUNOLOGIC FACTOR; VITAMIN D;

ACUTE MYELOBLASTIC LEUKEMIA; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AUTOPHAGY; BREAST CANCER; BREAST CANCER CELL LINE; CANCER STEM CELL; CELL DEATH; CELL DIFFERENTIATION; CELL PROLIFERATION; CHEMOPROPHYLAXIS; COLON CANCER; COLON CARCINOMA; COLORECTAL CANCER; DNA REPAIR; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; GENE CONTROL; GENE EXPRESSION; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOREGULATION; KIDNEY METASTASIS; LIVER CELL CARCINOMA; LYMPHOMA; MYELODYSPLASTIC SYNDROME; NEOPLASM; NEUROBLASTOMA; NON MELANOMA SKIN CANCER; NONHUMAN; OSTEOSARCOMA; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROSTAGLANDIN METABOLISM; PROSTAGLANDIN SYNTHESIS; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROSTATE CARCINOMA; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS REGULATION; REVIEW; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH; VITAMIN D METABOLISM; ANALOGS AND DERIVATIVES; ANIMAL; BREAST NEOPLASMS; CHEMISTRY; CLINICAL TRIAL (TOPIC); COLORECTAL NEOPLASMS; FEMALE; MALE; NEOPLASMS; PROSTATIC NEOPLASMS; TRENDS;

SCOPUS;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOPREVENTION; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; FEMALE; GROWTH INHIBITORS; HUMANS; IMMUNOLOGIC FACTORS; MALE; NEOPLASMS; PROSTATIC NEOPLASMS; VITAMIN D;

EID: 84939151534     PISSN: 13880209     EISSN: 17445116     Source Type: Journal    
DOI: 10.3109/13880209.2014.988274     Document Type: Review

References (415)

1. Abe E, Miyaura C, Sakagami H, et al. (2004). Differentiation of mouse myeloid leukemia cells induced by 1 alpha, 25-dihydroxyvitamin D3. Proc Natl Acad Sci USA 78:4990-4.
2. Abe-Hashimoto J, Kikuchi T, Matsumoto T, et al. (1993). Antitumor effect of 22-oxa-calcitriol, a noncalcemic analogue of calcitriol, in athymic mice implanted with human breast carcinoma and its synergism with tamoxifen. Cancer Res 53:2534-7.
3. 3, inhibits the growth of human breast cancer in vitro and in vivo without causing hypercalcemia. Endocrinology 129:832-7.
4. Adorini L, Penna G, Amuchastegui S, et al. (2007). Inhibition of prostate growth and inflammation by the vitamin D receptor agonist BXL-628 (elocalcitol). J Steroid Biochem 103:689-93.
5. Aggarwal BB. (2004). Nuclear factor-kappaB: The enemy within. Cancer Cell 6:203-8.
6. Agoston ES, Hatcher MA, Kensler TW, Posner GH. (2006). Vitamin D analogs as anti-carcinogenic agents. Anticancer Agents Med Chem 6:53-71.
7. Ajibade AA, Kirk JS, Karasik E, et al. (2014). Early growth inhibition is followed by increased metastatic disease with vitamin D (calcitriol) treatment in the TRAMP model of prostate cancer. PLoS One 9:e89555.
8. 3 analog, EB1089, inhibits growth of subcutaneous xenografts of the human colon cancer cell line, LoVo, in a nude mouse model. Dis Colon Rectum 40:317-21.
9. Akiyama N, Miyazawa K, Kanda Y, et al. (2010). Multicenter phase II trial of vitamin K (2) monotherapy and vitamin K (2) plus 1alphahydroxyvitamin D (3) combination therapy for low-risk myelodysplastic syndromes. Leuk Res 34:1151-7.
10. 3, calcipotriol and FTY720 on the expression of surface molecules and cytolytic activities of human natural killer cells and dendritic cells. Toxins (Basel) 5:1932-47.
11. An BS, Tavera-Mendoza LE, Dimitrov V, et al. (2010). Stimulation of Sirt1-regulated FoxO protein function by the ligand-bound vitamin D receptor. Mol Cell Biol 30:4890-900.
12. Anderson LN, Cotterchio M, Vieth R, Knight JA. (2010). Vitamin D and calcium intakes and breast cancer risk in pre- and postmenopausal women. Am J Clin Nutr 91:1699-707.
13. Anderson MG, Nakane M, Ruan X, et al. (2006). Expression of VDR and CYP24A1 mRNA in human tumors. Cancer Chemoth Pharm 57:234-40.
14. 3, a less calcemic vitamin D analog. J Cell Biochem 104:1832-42.
15. Arai MA, Kittaka A. (2006). Novel 2-alkyl-1alpha, 25-dihydroxy-19-norvitamin D3: Efficient synthesis with Julia olefination, evaluation of biological activity and development of new analyzing system for co-activator recruitment. Anticancer Res 26:2621-31.
16. Arai MA, Takeyama K, Ito S, et al. (2007). High-throughput system for analyzing ligand-induced cofactor recruitment by vitamin D receptor. Bioconjug Chem 18:614-20.
17. Armas LA, Dowell S, Akhter M, et al. (2007). Ultraviolet-B radiation increases serum 25-hydroxyvitamin D levels: The effect of UVB dose and skin color. J Am Acad Dermatol 57:588-93.
18. Baldwin AS. (2012). Regulation of cell death and autophagy by IKK and NF-κB: Critical mechanisms in immune function and cancer. Immunol Rev 246:327-45.
19. 3 prevents DNA damage and restores antioxidant enzymes in rat hepatocarcinogenesis induced by diethylnitrosamine and promoted by phenobarbital. World J Gastroenterol 10:1268-75.
20. 3 against oxidative stress in nonmalignant human prostate epithelial cells. Int J Cancer 122:2699-706.
21. Bao BY, Ting HJ, Hsu JW, et al. (2010). Down-regulation of NF-kappaB signals is involved in loss of 1alpha, 25-dihydroxyvitamin D3 responsiveness. J Steroid Biochem Mol Biol 120:11-21.
22. Bao BY, Yao J, Lee YF. (2006). 1Alpha, 25-dihydroxyvitamin D3 suppresses interleukin-8-mediated prostate cancer cell angiogenesis. Carcinogenesis 27:1883-93.
23. Beer TM, Ryan CW, Venner PM; ASCENT (AIPC Study of Calcitriol ENhancing Taxotere) Investigators, et al. (2008). Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: Results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel. Cancer 112:326-30.
24. Beildeck ME, Islam M, Shah S, et al. (2009). Control of TCF-4 expression by VDR and vitamin D in the mouse mammary gland and colorectal cancer cell lines. PLoS One 4:e7872.
25. 3 (Calcitriol) inhibits hypoxia-inducible factor-1/vascular endothelial growth factor pathway in human cancer cells. Mol Cancer Ther 6:1433-9.
26. 3 analog. Anticancer Drugs 21:609-18.
27. Bernardi RJ, Johnson CS, Modzelewski RA, Trump DL. (2002). Antiproliferative effects of 1alpha, 25-dihydroxyvitamin D (3) and vitamin D analogs on tumor-derived endothelial cells. Endocrinology 143:2508-14.
28. Bertone-Johnson ER, Chen WY, Holick MF, et al. (2005). Plasma 25-hydroxyvitamin D and 1, 25-dihydroxyvitamin D and risk of breast cancer. Cancer Epidem Biomarkers Prev 14:1991-7.
29. Bessler H, Djaldetti M. (2012). 1α, 25-Dihydroxyvitamin D3 modulates the interaction between immune and colon cancer cells. Biomed Pharmacother 66:428-32.
30. Bettoun DJ, Buck DW, Lu J, et al. (2002). A vitamin D receptor-Ser/Thr phosphatase-p70 S6 kinase complex and modulation of its enzymatic activities by the ligand. J Biol Chem 277:24847-50.
31. 3 is independent of nuclear receptor binding. J Biol Chem 270:15962-5.
32. 3 primes acute promyelocytic cells for TPA-induced monocytic differentiation through both PKC and tyrosine phosphorylation cascades. Exp Cell Res 222:61-9.
33. Bhatia V, Saini MK, Shen X, et al. (2009). EB1089 inhibits the parathyroid hormone-related protein enhanced bone metastasis and xenograft growth of human prostate cancer cells. Mol Cancer Ther 8:1787-98.
34. Bikle DD. (2012). Vitamin D and the skin: Physiology and pathophysiology. Rev Endocr Metab Disord 13:3-19.
35. Binderup L, Bramm E. (1988). Effects of a novel vitamin D analogue MC903 on cell proliferation and differentiation in vitro and on calcium metabolism in vivo. Biochem Pharmacol 37:889-95.
36. Binderup L, Latini S, Binderup E, et al. (1991). 20-Epi-vitamin D3 analogues: A novel class of potent regulators of cell growth and immune responses. Biochem Pharmacol 42:1569-75.
37. Bizzarri M, Cucina A, Valente MG, et al. (2003). Melatonin and vitamin D3 increase TGF-beta1 release and induce growth inhibition in breast cancer cell cultures. J Surg Res 110:332-7.
38. Blomberg Jensen M, Andersen CB, Nielsen JE, et al. (2010). Expression of the vitamin D receptor, 25-hydroxylases, 1alpha-hydroxylase and 24-hydroxylase in the human kidney and renal clear cell cancer. J Steroid Biochem Mol Biol 121:376-82.
39. Blutt SE, McDonnell TJ, Polek TC, Weigel NL. (2000). Calcitriolinduced apoptosis in LNCaP cells is blocked by overexpression of Bcl-2. Endocrinology 141:10-17.
40. Bogh MK, Schmedes AV, Philipsen PA, et al. (2010). Vitamin D production after UVB exposure depends on baseline vitamin D and total cholesterol but not on skin pigmentation. J Invest Dermatol 130:546-53.
41. Bouillon R, Carmeliet G, Verlinden L, et al. (2008). Vitamin D and human health: Lessons from vitamin D receptor null mice. Endocr Rev 29:726-76.
42. Bower M, Colston KW, Stein RC, et al. (1991). Topical calcipotriol treatment in advanced breast cancer. Lancet 337:701-2.
43. Boyle BJ, Zhao XY, Cohen P, Feldman D. (2001). Insulin-like growth factor binding protein-3 mediates 1 alpha, 25-dihydroxyvitamin D (3) growth inhibition in the LNCaP prostate cancer cell line through p21/WAF1. J Urol 165:1319-24.
44. Brown AJ, Slatopolsky E. (2008). Vitamin D analogs: Therapeutic applications and mechanisms for selectivity. Mol Aspects Med 29:433-52.
45. Brozek W, Manhardt T, Kállay E, et al. (2012). Relative expression of vitamin D hydroxylases, CYP27B1 and CYP24A1, and of cyclooxygenase-2 and heterogeneity of human colorectal cancer in relation to age, gender, tumor location, and malignancy: Results from factor and cluster analysis. Cancers (Basel) 4:763-76.
46. Brozyna AA, Jozwicki W, Janjetovic Z, Slominski AT. (2011). Expression of vitamin D receptor decreases during progression of pigmented skin lesions. Hum Pathol 42:618-31.
47. Byers SW, Rowlands T, Beildeck M, Bong YS. (2012). Mechanism of action of vitamin D and the vitamin D receptor in colorectal cancer prevention and treatment. Rev Endocr Metab Disord 13:31-8.
48. Byrne B, Welsh J. (2007). Identification of novel mediators of Vitamin D signaling and 1, 25 (OH) 2D3 resistance in mammary cells. J Steroid Biochem Mol Biol 103:703-7.
49. 3 on breast and prostate cancer cells are associated with induction of BRCA1 gene expression. Oncogene 19:5091-7.
50. Cantorna MT. (2012). Vitamin D, multiple sclerosis and inflammatory bowel disease. Arch Biochem Biophys 523:103-6.
51. Cao X, Ross FP, Zhang L, et al. (1993). Cloning of the promoter for the avian integrin beta 3 subunit gene and its regulation by 1, 25-dihydroxyvitamin D3. J Biol Chem 268:27371-80.
52. Cardús A, Parisi E, Gallego C, et al. (2006). 1, 25-Dihydroxyvitamin D3 stimulates vascular smooth muscle cell proliferation through a VEGF-mediated pathway. Kidney Int 69:1377-84.
53. Chan AT, Giovannucci EL. (2010). Primary prevention of colorectal cancer. Gastroenterology 138:2029-43.
54. Chaudhry M, Sundaram S, Gennings C, et al. (2001). The vitamin D3 analog, ILX-23-7553, enhances the response to adriamycin and irradiation in MCF-7 breast tumor cells. Cancer Chemother Pharmacol 47:429-36.
55. 3. Am J Physiol Gastrointest Liver Physiol 283:864-74.
56. Chen TC, Holick MF. (2003). Vitamin D and prostate cancer prevention and treatment. Trends Endocrinol Metab 14:423-30.
57. Chen TC, Holick MF, Lokeshwar BL, et al. (2003). Evaluation of vitamin D analogs as therapeutic agents for prostate cancer. Recent Res Cancer 164:273-88.
58. Chen TC, Kittaka A. (2011). Novel vitamin D analogs for prostate cancer therapy. ISRN Urolol 2011:301490. doi:10.5402/2011/301490.
59. Chen TC, Sakaki T, Yamamoto K, Kittaka A. (2012). The roles of cytochrome P450 enzymes in prostate cancer development and treatment. Anticancer Res 32:291-8.
60. Chiang KC, Yeh CN, Chen SC, et al. (2012). MART-10, a new generation of vitamin D analog, is more potent than 1α, 25-dihydroxyvitamin D (3) in inhibiting cell proliferation and inducing apoptosis in ER+ MCF-7 breast cancer cells. Evid Based Complement Alternat Med, 2012:310872. doi: 10.1155/2012/310872.
61. Chiang KC, Chen SC, Yeh CN, et al. (2014). MART-10, a less calcemic vitamin D analog, is more potent than 1α, 25-dihydroxyvitamin D3 in inhibiting the metastatic potential of MCF-7 breast cancer cells in vitro. Steroid Biochem Mol Biol 139:54-60.
62. 3 stimulates differentiation of squamous carcinoma cell line in the raft culture. Anticancer Res 16:337-47.
63. Choi M, Makishima M. (2009). Therapeutic applications for novel nonhypercalcemic vitamin D receptor ligands. Expert Opin Ther Pathol 19:593-606.
64. Chung I, Han G, Seshadri M, et al. (2009). Role of vitamin D receptor in the antiproliferative effects of calcitriol intumor-derived endothelial cells and tumor angiogenesis in vivo. Cancer Res 69:967-75.
65. Chung I, Wong MK, Flynn G, et al. (2006). Differential antiproliferative effects of calcitriol on tumor-derived and matrigel-derived endothelial cells. Cancer Res 66:8565-73.
66. Cianferotti L, Cox M, Skorija K, Demay MB. (2007). Vitamin D receptor is essential for normal keratinocyte stem cell function. Proc Natl Acad Sci USA 104:9428-33.
67. Circu ML, Aw TY. (2010). Reactive oxygen species, cellular redox systems, and apoptosis. Free Radic Biol Med 48:749-62.
68. Clinckspoor I, Hauben E, Verlinden L, et al. (2012). Altered expression of key players in vitamin D metabolism and signaling in malignant and benign thyroid tumors. J Histochem Cytochem 60:502-11.
69. Colston K, Colston MJ, Feldman D. (1981). 1, 25-Dihydroxyvitamin D3 and malignant melanoma: The presence of receptors and inhibition of cell growth in culture. Endocrinology 108:1083-6.
70. Colston KW, Chander SK, Mackay AG, Coombes RC. (1992). Effects of synthetic vitamin D analogues on breast cancer cell proliferation in vivo and in vitro. Biochem Pharmacol 44:693-702.
71. Colston KW, Mackay AG, James SY, et al. (1992a). EB1089: A new vitamin D analogue that inhibits the growth of breast cancer cells in vivo and in vitro. Biochem Pharmacol 44:2273-80.
72. Colston KW, Perks CM, Xie SP, Holly JM. (1998). Growth inhibition of both MCF-7 and Hs578T human breast cancer cell lines by vitamin D analogues is associated with increased expression of insulin-like growth factor binding protein-3. J Mol Endocrinol 20:157-62.
73. Colston KW, Hansen CM. (2002). Mechanisms implicated in the growth regulatory effects of vitamin D in breast cancer. Endocr Relat Cancer 9:45-59.
74. 3 levels in breast and ovarian cancer. Anticancer Res 32:351-7.
75. Crescioli C, Villari D, Forti G, et al. (2002). Des (1-3) IGF-I-stimulated growth of human stromal BPH cells is inhibited by a vitamin D3 analogue. Mol Cell Endocrinol 198:69-75.
76. Cross HS, Bises G, Lechner D, et al. (2005). The vitamin D endocrine system of the gut - Its possible role in colorectal cancer prevention. J Steroid Biochem Mol Biol 97:121-8.
77. Cross HS, Nittke T, Kallay E. (2011). Colonic vitamin D metabolism: Implications for the pathogenesis of inflammatory bowel disease and colorectal cancer. Mol Cell Endocrinol 347:70-9.
78. Cross HS, Nittke T, Peterlik M. (2009). Modulation of vitamin D synthesis and catabolism in colorectal mucosa: A new target for cancer prevention. Anticancer Res 29:3705-12.
79. Cunningham D, Gilchrist NL, Cowan RA, et al. (1985). Alfacalcidol as a modulator of growth of low grade non-Hodgkin's lymphomas. Br Med J (Clin Res Ed) 291:1153-5.
80. Dalhoff K, Dancey J, Astrup L, et al. (2003). A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma. Br J Cancer 89:252-7.
81. Dalirsani Z, Farajnia S, Javadzadeh Y, et al. (2012). The effects of 5-fluorouracil alone and in combination with 13-cis retinoic acid and vitamin D3 on human oral squamous cell carcinoma lines. J Contemp Dent Pract 13:345-50.
82. Daniel C, Schroder O, Zahn N, et al. (2007). The TGF beta/Smad 3-signaling pathway is involved in butyrate-mediated vitamin D receptor (VDR)-expression. J Cell Biochem 102:1420-31.
83. 3 and its analogues. Cell Death Differ 5:946-52.
84. Davis JS, Wu X. (2012). Current state and future challenges of chemoprevention. Discov Med 13:385-90.
85. Deeb KK, Trump DL, Johnson CS. (2007). Vitamin D signalling pathways in cancer: Potential for anticancer therapeutics. Nat Rev Cancer 7:684-700.
86. 3 analogue, EB1089, through promotion of autophagy and interference with proliferative recovery. Mol Cancer Ther 5:2786-97.
87. 3 and its analogue EB1089 in colorectal adenoma and carcinoma cells: Possible implications for prevention and therapy. Cancer Res 60:2304-12.
88. Di Cunto F, Topley G, Calautti E, et al. (1998). Inhibitory function of p21Cip1/WAF1 in differentiation of primary mouse keratinocytes independent of cell cycle control. Science 280:1069-72.
89. 3. Prostate 26:72-9.
90. Dröge W. (2003). Autophagy and aging - Importance of amino acid levels. Mech Ageing Dev 225:161-8.
91. Edfeldt K, Liu PT, Chun R, et al. (2010). T-cell cytokines differentially control human monocyte antimicrobial responses by regulating vitamin D metabolism. Proc Natl Acad Sci USA 107:22593-8.
92. Eide MJ, Johnson DA, Jacobsen GR, et al. (2011). Vitamin D and nonmelanoma skin cancer in a health maintenance organization cohort. Arch Dermatol 147:1379-84.
93. 3 analog combined with 9-cis-retinoic acid markedly inhibits colony growth of prostate cancer cells. Prostate 40:141-9.
94. Engel P, Fagherazzi G, Boutten A, et al. (2010). Serum 25 (OH) vitamin D and risk of breast cancer: A nested case-control study from the French E3N cohort. Cancer Epidemiol Biomarkers Prev 19:2341-50.
95. Engeset D, Alsaker E, Lund E, et al. (2006). Fish consumption and breast cancer risk. The European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer 119:175-82.
96. 3 receptor (VDR) expression in HC-11 mammary cells: Regulation by growthmodulatory agents, differentiation, and Ha-ras transformation. Breast Cancer Res Treat 54:123-33.
97. Evans TR, Colston KW, Lofts FJ, et al. (2002). A phase II trial of the vitamin D analogue Seocalcitol (EB1089) in patients with inoperable pancreatic cancer. Br J Cancer 86:680-5.
98. Fedirko V, Bostick RM, Flanders WD, et al. (2009). Effects of vitamin D and calcium on proliferation and differentiation in normal colon mucosa: A randomized clinical trial. Cancer Epidemiol Biomarkers Prev 18:2933-41.
99. Fedirko V, Bostick RM, Long Q, et al. (2010). Effects of supplemental vitamin D and calcium on oxidative DNA damage marker in normal colorectal mucosa: A randomized clinical trial. Cancer Epidemiol Biomarkers Prev 19:280-91.
100. Feldman D, Krishnan AV, Swami S, et al. (2014). The role of vitamin D in reducing cancer risk and progression. Nat Rev Cancer 14:342-57.
101. 2 genes and the angiogenic phenotype of human colon carcinoma cells. Oncogene 24:6533-44.
102. Fischer J, Wang TT, Kaldre D, et al. (2012). Synthetically accessible non-secosteroidal hybrid molecules combining vitamin D receptor agonism and histone deacetylase inhibition. Chem Biol 19:963-71.
103. 3 as a therapeutic agent for androgen-dependent prostate cancer. Anticancer Res 29:3547-53.
104. Flanagan L, Packman K, Juba B, et al. (2003). Efficacy of Vitamin D compounds to modulate estrogen receptor negative breast cancer growth and invasion. J Steroid Biochem Mol Biol 84:181-92.
105. Fleet JC, De Smet M, Johnson R, Li Y. (2012). Vitamin D and cancer: A review of molecular mechanisms. Biochem J 441:61-76.
106. Flores O, Wang Z, Knudsen KE, Burnstein KL. (2010). Nuclear targeting of cyclin-dependent kinase 2 reveals essential roles of cyclindependent kinase 2 localization and cyclin E in vitamin D-mediated growth inhibition. Endocrinology 151:896-908.
107. Flynn G, Chung I, Yu WD, et al. (2006). Calcitriol (1, 25-dihydroxycholecalciferol) selectively inhibits proliferation of freshly isolated tumor-derived endothelial cells and induces apoptosis. Oncology 70:447-57.
108. Freedman DM, Looker AC, Chang SC, Graubard BI. (2007). Prospective study of serum vitamin D and cancer mortality in the United States. J Natl Cancer Inst 99:1594-602.
109. 3-1alpha-hydroxylase in normal and malignant breast tissue. Anticancer Res 26:2615-20.
110. Fukumoto S. (2014). Phosphate metabolism and vitamin D. Bonekey Rep 3:497. doi:10.1038/bonekey.2013.231.
111. Funato K, Miyazawa K, Yaguchi M, et al. (2002). Combination of 22-oxa-1, 25-dihydroxyvitamin D (3), a vitamin D (3) derivative, with vitamin K (2) (VK2) synergistically enhances cell differentiation but suppresses VK2-inducing apoptosis in HL-60 cells. Leukemia 16:1519-27.
112. 3, a natural metabolite of calcitriol. J Steroid Biochem Mol Biol 89:427-31.
113. Gandini S, Boniol M, Haukka J, et al. (2011). Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. Int J Cancer 128:1414-24.
114. 3 stimulates myogenic differentiation by inhibiting cell proliferation and modulating the expression of promyogenic growth factors and myostatin in C2C12 skeletal muscle cells. Endocrinology 152:2976-86.
115. Garland CF, Gorham ED, Mohr SB, et al. (2007). Vitamin D and prevention of breast cancer: Pooled analysis. J Steroid Biochem Mol Biol 103:708-11.
116. Gaschott T, Steinmeyer A, Steinhilber D, Stein J. (2002). ZK156718 a low calcemic, antiproliferative, and prodifferentiating vitamin D analog. Biochem Biophys Res Commun 290:504-9.
117. 3 induces elevated expression of the cell cycle inhibitor p18 in a squamous cell carcinoma cell line of the head and neck. J Oral Pathol Med 35:472-8.
118. 2 in patients with clinically localized prostate cancer and high grade pin. Prostate 9:970-8.
119. Geng S, Zhou S, Glowacki J. (2011). Effects of 25-hydroxyvitamin D (3) on proliferation and osteoblast differentiation of human marrow stromal cells require CYP27B1/1a-hydroxylase. J Bone Miner Res 26:1145-53.
120. Ghous Z, Akhter J, Pourgholami MH, Morris DL. (2008). Inhibition of hepatocellular cancer by EB1089: In vitro and in vivo study. Anticancer Res 28:3757-61.
121. Giardina C, Madigan JP, Tierney CA, et al. (2012). Vitamin D resistance and colon cancer prevention. Carcinogenesis 33:475-82.
122. Gilbert R, Metcalfe C, Fraser WD, et al. (2012). Associations of circulating retinol, vitamin E, and 1, 25-dihydroxyvitamin D with prostate cancer diagnosis, stage, and grade. Cancer Causes Control 23:1865-73.
123. Giovannucci E. (2010). Epidemiology of vitamin D and colorectal cancer: Casual or causal link? J Steroid Biochem Mol Biol 121:349-54.
124. Gocek E, Studzinski GP. (2009). Vitamin D and differentiation in cancer. Crit Rev Clin Lab Sci 46:190-209.
125. 3. FASEB J 19:1067-77.
126. 3 in human colon cancer cells. Anticancer Res 26:2669-81.
127. 3 on DNA repair provide new strategies for breast cancer treatment. J Steroid Biochem Mol Biol 144:59-64.
128. Goodwin PJ, Ennis M, Pritchard KI, et al. (2009). Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. J Clin Oncol 27:3757-63.
129. Gulliford T, English J, Colston KW, et al. (1998). A phase I study of the vitamin D analogue EB1089 in patients with advanced breast and colorectal cancer. Br J Cancer 78:6-13.
130. 3 analogue, KH1060 in human neuroblastoma: Induction of RAR-beta and p21 (Cip1). Cancer Lett 190:51-60.
131. 3 in prostate cancer. Mol Cancer Ther 1:667-77.
132. 3 induces elevated expression of the cell cycle-regulating genes P21 and P27 in squamous carcinoma cell lines of the head and neck. Acta Otolaryngol 121:103-9.
133. 3 inhibits the invasive potential of human breast cancer cells in vitro. Clin Exp Metastasis 12:195-202.
134. 3 inhibits tumor growth and metastasis of a murine osteosarcoma model. Anticancer Res 21:321-4.
135. Harrison JS, Bershadskiy A. (2012). Clinical experience using vitamin D and analogs in the treatment of myelodysplasia and acute myeloid leukemia: A review of the literature. Leuk Res Treatment 2012:125814. doi:10.1155/2012/125814.
136. 3: 20-epi-ED-71]. J Steroid Biochem Mol Biol 121:25-8.
137. 3: Genomic and non-genomic mechanisms. Best Pract Res Clin Endocrinol Metab Endocrinol Metab 25:543-59.
138. Haussler MR, Whitfield GK, Kaneko I, et al. (2013). Molecular mechanisms of vitamin D action. Calcif Tissue Int 92:77-98.
139. 3 in the human prostatic carcinoma cell line ALVA-31. J Steroid Biochem Mol Biol 58:277-88.
140. Hendrickson WK, Flavin R, Kasperzyk JL, et al. (2011). Vitamin D receptor protein expression in tumor tissue and prostate cancer progression. J Clin Oncol 29:2378-85.
141. Henry HL. (2011). Regulation of vitamin D metabolism. Best Pract Res Clin Endocrinol Metab 25:531-41.
142. Hershberger PA, Yu WD, Modzelewski RA, et al. (2001). Calcitriol (1, 25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis. Clin Cancer Res 7:1043-51.
143. Hewison M. (2011). Vitamin D and innate and adaptive immunity. Vitam Horm 86:23-62.
144. Höbaus J, Thiem U, Hummel DM, Kallay E. (2013). Role of calcium, vitamin D, and the extrarenal vitamin D hydroxylases in carcinogenesis. Anticancer Agents Med Chem 13:20-35.
145. Hofer H, Ho GM, Peterlik M, et al. (1999). Biological effects of 1alphahydroxy- and 1beta-(hydroxymethyl)-vitamin D compounds relevant for potential colorectal cancer therapy. J Pharmacol Exp Ther 291:450-5.
146. Holick MF. (2013). Vitamin D. Sunlight and cancer connection. Anticancer Agents Med Chem 13:70-82.
147. 3 prolong survival time of mice inoculated with myeloid leukemia cells. Proc Natl Acad Sci USA 80:201-4.
148. Horváth HC, Lakatos P, Kósa JP, et al. (2010). The candidate oncogene CYP24A1: A potential biomarker for colorectal tumorigenesis. J Histochem Cytochem 58:277-85.
149. Høyer-Hansen M, Bastholm L, Mathiasen IS, et al. (2005). Vitamin D analog EB1089 triggers dramatic lysosomal changes and Beclin 1-mediated autophagic cell death. Cell Death Differ 12:1297-309.
150. Høyer-Hansen M, Bastholm L, Szyniarowski P, et al. (2007). Control of macroautophagy by calcium, calmodulin-dependent kinase kinasebeta, and Bcl-2. Mol Cell 25:193-205.
151. Hoyer-Hansen M, Nordbrandt SP, Jäättelä M. (2010). Autophagy as a basis for the health-promoting effects of vitamin D. Trends Mol Med 16:295-302.
152. 3-driven signals for myeloid cell differentiation-implications for differentiation therapy. Leuk Res 34:553-65.
153. 3. Am J Pathol 178:872-80.
154. Hussain T, Gupta S, Mukhtar H. (2003). Cyclooxygenase-2 and prostate carcinogenesis. Cancer Lett 191:125-35.
155. 3 and its analog EB1089. Int J Oncol 13:137-43.
156. 3 with 3-hydroxypropyl group generates an analogue with enhanced chemotherapeutic potency in PC-3 prostate cancer cells. J Steroid Biochem Mol Biol 127:269-75.
157. 3 and 9-cis-retinoic acid directly inhibits human telomerase reverse transcriptase transcription in prostate cancer cells. Mol Cancer Ther 2:739-46.
158. 3, hypercalcemia, and growth suppression of 7, 12-dimethylbenz[a]anthracene-induced rat mammary tumors. Breast Cancer Res Treat 22:133-40.
159. 3 of colon carcinogenesis induced by azoxymethane in Wistar rats. Int J Cancer 81:730-3.
160. Ishihara J, Inoue M, Iwasaki M, et al. (2008). Dietary calcium, vitamin D, and the risk of colorectal cancer. Am J Clin Nutr 88:1576-83.
161. Istfan NW, Person KS, Holick MF, Chen TC. (2007). 1Alpha, 25-Dihydroxyvitamin D and fish oil synergistically inhibit G1/S-phase transition in prostate cancer cells. J Steroid Biochem Mol Biol 103:726-30.
162. James SY, Williams MA, Newland AC, Colston KW. (1999). Leukemia cell differentiation: Cellular and molecular interactions of retinoids and vitamin D. Gen Pharmacol 32:143-54.
163. 3 derivatives. Br J Cancer 105:1874-84.
164. Jäpelt RB, Jakobsen J. (2013). Vitamin D in plants: A review of occurrence, analysis, and biosynthesis. Front Plant Sci 4:136.
165. Jenab M, Bueno-De-Mesquita HB, Ferrari P, et al. (2010). Association between pre-diagnostic circulating vitamin D concentration and risk of colorectal cancer in European populations: A nested case-control study. Biochem Med J 340:b5500.
166. Jensen SS, Madsen MW, Lukas J, et al. (2001). Inhibitory effects of 1alpha, 25-dihydroxyvitamin D (3) on the G (1)-S phase-controlling machinery. Mol Endocrinol 15:1370-80.
167. 3 in ovarian cancer cells mediated through the induction of GADD45 via an exonic enhancer. J Biol Chem 278:48030-40.
168. Jiang F, Robin AM, Katakowski M, et al. (2003b). Photodynamic therapy with photofrin in combination with buthionine sulfoximine (BSO) of human glioma in the nude rat. Lasers Med Sci 18:128-33.
169. John EM, Schwartz GG, Koo J, et al. (2007). Sun exposure, vitamin D receptor gene polymorphisms, and breast cancer risk in a multiethnic population. Am J Epidemiol 166:1409-19.
170. Jones G, Prosser DE, Kaufmann M. (2012). 25-Hydroxyvitamin D-24-hydroxylase (CYP24A1): Its important role in the degradation of vitamin D. Arch Biochem Biophys 523:9-18.
171. Jones G, Prosser DE, Kaufmann M. (2014). Cytochrome P450-mediated metabolism of vitamin D. J Lipid Res 55:13-31.
172. 3 suppresses telomerase expression and human cancer growth through MicroRNA-498. J Biol Chem 287:41297-309.
173. 3, maxacalcitol, on the proliferation of pancreatic cancer cell lines. Steroid Biochem Mol Biol 97:173-7.
174. Ke HZ, Qi H, Crawford DT, et al. (2005). A new vitamin D analog, 2MD, restores trabecular and cortical bone mass and strength in ovariectomized rats with established osteopenia. J Bone Miner Res 20:1742-55.
175. Kemmis CM, Welsh J. (2008). Mammary epithelial cell transformation is associated with deregulation of the vitamin D pathway. J Cell Biochem 105:980-8.
176. Khan QJ, Kimler BF, Fabian CJ. (2010). The relationship between vitamin D and breast cancer incidence and natural history. Curr Oncol Rep 12:136-42.
177. Kikuchi H, Murakami S, Suzuki S, et al. (2007). Chemopreventive effect of a vitamin D (3) analog, alfacalcidol, on colorectal carcinogenesis in mice with ulcerative colitis. Anticancer Drugs 18:1183-7.
178. Kim J, Lim SY, Shin A, et al. (2009). Fatty fish and fish omega-3 fatty acid intakes decrease the breast cancer risk: A case-control study. BMC Cancer 9:216.
179. Kim M, Mirandola L, Pandey A, et al. (2012). Application of vitamin D and derivatives in hematological malignancies. Cancer Lett 319:8-22.
180. 3. Biochem Pharmacol 41:1601-6.
181. Kittaka A, Yoshida A, Chiang KC, et al. (2012). Potent 19-norvitamin D analogs for prostate and liver cancer therapy. Future Med Chem 4:2049-65.
182. Knight JA, Lesosky M, Barnett H, et al. (2007). Vitamin D and reduced risk of breast cancer: A population-based case control study. Cancer Epidem Biomarkers Prev 16:422-9.
183. 3 enhances the expression of transforming growth factor beta 1 and its latent form binding protein in cultured breast carcinoma cells. Cancer Res 55:1540-6.
184. Komagata S, Nakajima M, Takagi S, et al. (2009). Human CYP24 catalyzing the inactivation of calcitriol is post-transcriptionally regulated by miR-125b. Mol Pharmacol 76:702-9.
185. 3 analogs and paclitaxel on the growth of MCF-7 breast cancer cells in vivo. Breast Cancer Res Treat 53:113-20.
186. Kovalenko PL, Zhang Z, Cui M, et al. (2010). 1, 25-Dihydroxyvitamin D-mediated orchestration of anticancer, transcript-level effects in the immortalized, non-transformed prostate epithelial cell line, RWPE1. BMC Genomics 11:26.
187. 3 and its structural analogs on gene expression in cancer cells: A microarray approach. Anticancer Res 29:3471-83.
188. Krill D, De Flavia P, Dhir R, et al. (2001). Expression patterns of vitamin D receptor in human prostate. J Cell Biochem 82:566-72.
189. Krishnan AV, Feldman D. (2010). Molecular pathways mediating the anti-inflammatory effects of calcitriol: Implications for prostate cancer chemoprevention and treatment. Endocr Relat Cancer 17:19-38.
190. Krishnan AV, Feldman D. (2011). Mechanisms of the anti-cancer and anti-inflammatory actions of vitamin D. Annu Rev Pharmacol Toxicol 10:311-36.
191. Krishnan AV, Moreno J, Nonn L, et al. (2007). Novel pathways that contribute to the anti-proliferative and chemopreventive activities of calcitriol in prostate cancer. J Steroid Biochem Mol Biol 103:694-702.
192. Krishnan AV, Shinghal R, Raghavachari N, et al. (2004). Analysis of vitamin D-regulated gene expression in LNCaP human prostate cancer cells using cDNA microarrays. Prostate 59:243-51.
193. Krishnan AV, Swami S, Feldman D. (2012). The potential therapeutic benefits of vitamin D in the treatment of estrogen receptor positive breast cancer. Steroids 77:1107-12.
194. Kristal AR, Till C, Song X, et al. (2014). Plasma vitamin D and prostate cancer risk: Results from the selenium and vitamin E cancer prevention trial. Cancer Epidemiol Biomarkers Prev 23:1494-504.
195. 2: Antitumor activity against leukemia, myeloma, and colon cancer cells. J Natl Cancer Inst 95:896-905.
196. 2 (a novel, noncalcemic vitamin D analogue), combined with arsenic trioxide, has potent antitumor activity against myeloid leukemia. Cancer Res 65:2488-97.
197. Kure S, Nosho K, Baba Y, et al. (2009). Vitamin D receptor expression is associated with PIK3CA and KRAS mutations in colorectal cancer. Cancer Epidem Biomarkers Prev 18:2765-72.
198. Lambert JR, Kelly JA, Shim M, et al. (2006). Prostate derived factor in human prostate cancer cells: Gene induction by vitamin D via a p53-dependent mechanism and inhibition of prostate cancer cell growth. J Cell Physiol 208:566-74.
199. Lankelma JM, Voorend DM, Barwari T, et al. (2010). Cathepsin L, target in cancer treatment? Life Sci 86:225-33.
200. Larriba MJ, Muñoz A. (2010). Mechanisms of resistance to vitamin D action in human cancer cells. In: Holick MF, ed. Vitamin D: Physiology, Molecular Biology, and Clinical Applications. New York, NY, USA: Humana Press, 325-33.
201. Larriba MJ, González-Sancho JM, Barbáchano A, et al. (2013). Vitamin D is a multilevel repressor of wnt/b-catenin signaling in cancer cells. Cancers (Basel) 5:1242-60.
202. 2) in women receiving chemotherapy for metastatic breast cancer: A feasibility trial. Cancer Biol Ther 14:476-80.
203. Lee HJ, Liu H, Goodman C, et al. (2006). Gene expression profiling changes induced by a novel Gemini vitamin D derivative during the progression of breast cancer. Biochem Pharmacol 72:332-43.
204. Lee HJ, Paul S, Atalla N, et al. (2008). Gemini vitamin D analogues inhibit estrogen receptor-positive and estrogen receptor-negative mammary tumorigenesis without hypercalcemic toxicity. Cancer Prev Res 1:1476-84.
205. Lee SJ, Lee YS, Zimmers TA, et al. (2010). Regulation of muscle mass by follistatin and activins. Mol Endocrinol 24:1998-2008.
206. Leto G, Sepporta MV, Crescimanno M, et al. (2010). Cathepsin L in metastatic bone disease: Therapeutic implications. Biol Chem 91:655-64.
207. 3 and its analogs in breast, prostate and colorectal cancer. Endocr Relat Cancer 20:R31-47.
208. Leyssens C, Verlinden L, Verstuyf A. (2014). The future of vitamin D analogs. Front Physiol 5:122. doi:10.3389/fphys.2014.00122.
209. Li Y, Brown PH. (2009). Prevention of ER-negative breast cancer. Recent Results Cancer Res 181:121-34.
210. 3 compounds in two isogenic MCF-7 breast cancer cell sublines. Oncogene 24:1385-95.
211. Liang G, Nan H, Qureshi AA, Han J. (2012). Pre-diagnostic plasma 25-hydroxyvitamin D levels and risk of non-melanoma skin cancer in women. PLoS One 7:e35211.
212. 3 analog EB1089 signaling on cell proliferation, differentiation, and immune system regulation. Mol Endocrinol 16:1243-56.
213. Liu G, Hu X, Chakrabarty S. (2010). Vitamin D mediates its action in human colon carcinoma cells in a calcium-sensing receptor-dependent manner: Downregulates malignant cell behavior and the expression of thymidylate synthase and survivin and promotes cellular sensitivity to 5-FU. Int J Cancer 126:631-9.
214. Lopes N, Sousa B, Martins D, et al. (2010). Alterations in Vitamin D signalling and metabolic pathways in breast cancer progression: A study of VDR, CYP27B1 and CYP24A1 expression in benign and malignant breast lesions Vitamin D pathways unbalanced in breast lesions. BMC Cancer 10:483.
215. 3 induces de novo E-cadherin expression in triple-negative breast cancer cells by CDH1-promoter demethylation. Anticancer Res 32:249-57.
216. Lowe L, Hansen CM, Senaratne S, Colston KW. (2003). Mechanisms implicated in the growth regulatory effects of vitamin D compounds in breast cancer cells. Results Cancer Res 164:99-110.
217. Lowe LC, Guy M, Mansi JL, et al. (2005). Plasma 25-hydroxyvitamin D concentrations, vitamin D receptor genotype and breast cancer risk in a UK Caucasian population. Eur J Cancer 41:1164-9.
218. 3 analogue EB1089 inhibits the proliferation of human laryngeal squamous carcinoma cells via p57. Mol Cancer Ther 7:1268-74.
219. Ma Y, Trump DL, Johnson CS. (2010). Vitamin D in combination cancer treatment. J Cancer 1:101-7.
220. Ma Y, Zhang P, Wang F, et al. (2011). Association between vitamin D and risk of colorectal cancer: A systematic review of prospective studies. J Clin Oncol 29:3775-82.
221. 3, displays enhanced antitumor activity through the induction of apoptosis in a squamous cell carcinoma model system. Cell Cycle 12:743-52.
222. Ma Y, Yu WD, Su B, et al. (2013b). Regulation of motility, invasion, and metastatic potential of squamous cell carcinoma by 1α, 25-dihydroxycholecalciferol. Cancer 119:563-74.
223. Maalmi H, Ordóñez-Mena JM, Schöttker B, Brenner H. (2014). Serum 25-hydroxyvitamin D levels and survival in colorectal and breast cancer patients: Systematic review and meta-analysis of prospective cohort studies. Eur J Cancer 50:1510-21.
224. Macejová D, Ondková S, Jakubíková L, et al. (2011). MNU-induced mammary gland carcinogenesis: Chemopreventive and therapeutic effects of vitamin D and Seocalcitol on selected regulatory vitamin D receptor pathways. Toxicol Lett 207:60-72.
225. 3 induce transcriptional attenuation at the cyclin D1 locus incolonic carcinoma cells. J Cell Physiol 218:638-42.
226. Maehr H, Rochel N, Lee HJ, et al. (2013). Diastereotopic and deuterium effects in Gemini. J Med Chem 56:3878-88.
227. Mäenpää PH, Väisänen S, Jääskeläinen T, et al. (2001). Vitamin D (3) analogs (MC 1288, KH 1060, EB1089, GS1558, and CB1093): Studies on their mechanism of action. Steroids 66:223-5.
228. Mantell DJ, Owens PE, Bundred NJ, et al. (2000). 1Alpha, 25-dihydroxyvitamin D (3) inhibits angiogenesis in vitro and in vivo. Circ Res 87:214-20.
229. Marchiani S, Bonaccorsi L, Ferruzzi P, et al. (2006). The vitamin D analogue BXL-628 inhibits growth factor-stimulated proliferation and invasion of DU145 prostate cancer cells. J Cancer Res Clin Oncol 132:408-16.
230. 24-stem celllike breast cancer cells in human tumors. J Clin Invest 121:2723-35.
231. Maruyama R, Aoki F, Toyota M, et al. (2006). Comparative genome analysis identifies the vitamin D receptor gene as a direct target of p53-mediated transcriptional activation. Cancer Res 66:4574-83.
232. Massagué J. (2008). TGF beta in cancer. Cell 134:215-30.
233. Massoner P, Colleselli D, Matscheski A, et al. (2009). Novel mechanism of IGF-binding protein-3 action on prostate cancer cells: Inhibition of proliferation, adhesion, and motility. Endocr Relat Cancer 16:795-808.
234. Mathiasen IS, Colston KW, Binderup L. (1993). EB1089, a novel vitamin D analogue, has strong antiproliferative and differentiation inducing effects on cancer cells. J Steroid Biochem 46:365-71.
235. Mathiasen IS, Lademann U, Jäättelä M. (1999). Apoptosis induced by vitamin D compounds in breast cancer cells is inhibited by Bcl-2 but does not involve known caspases or p53. Cancer Res 59:4848-56.
236. 3. Nucleic Acids Res 33:5521-32.
237. Matsumoto H, Iino Y, Koibuchi Y, et al. (1999). Antitumor effect of 22-oxacalcitriol on estrogen receptor-negative MDA-MB-231 tumors in athymic mice. Oncol Rep 6:349-52.
238. Matusiak D, Benya RV. (2007). CYP27A1 and CYP24 expression as a function of malignant transformation in the colon. J Histochem Cytochem 55:1257-64.
239. 31{alpha}-hydroxylase in normal and malignant human colon. Cancer Epidem Biomarkers Prev 14:2370-6.
240. 3 in prostate progenitor/stem cells. Cancer Res 71:5276-86.
241. McCullough ML, Bostick RM, Mayo TL. (2009). Vitamin D gene pathway polymorphisms and risk of colorectal, breast, and prostate cancer. Annu Rev Nutr 29:111-32.
242. Medioni J, Deplanque G, Ferrero JM, et al. (2014). Phase I safety and pharmacodynamic of inecalcitol, a novel VDR agonist with docetaxel in metastatic castration-resistant prostate cancer patients. Clin Cancer Res 20:4471-7.
243. Meeker S, Seamons A, Paik J, et al. (2014). Increased dietary Vitamin D suppresses MAPK signaling, colitis, and colon cancer. Cancer Res 74:4398-408.
244. Meephansan J, Komine M, Tsuda H, Ohtsuki M. (2012). Suppressive effect of calcipotriol on the induction of matrix metalloproteinase (MMP)-9 and MMP-13 in a human squamous cell carcinoma cell line. Clin Exp Dermatol 37:889-96.
245. Mellibovsky L, Díez A, Pérez-Vila E, et al. (1998). Vitamin D treatment in myelodysplastic syndromes. Br J Haematol 100:516-20.
246. 3. Studies in cultured bovine aortic endothelial cells and human dermal capillaries. J Clin Invest 83:1903-15.
247. Mehta RG, Peng X, Alimirah F, et al. (2012). Vitamin D and breast cancer: Emerging concepts. Cancer Lett 334:95-100.
248. Milczarek M, Chodyński M, Filip-Psurska B, et al. (2013a). Synthesis and biological activity of diastereomeric and geometric analogs of calcipotriol, PRI-2202 and PRI-2205, against human HL-60 leukemia and MCF-7 breast cancer cells. Cancers (Basel) 5:1355-78.
249. Milczarek M, Psurski M, Kutner A, Wietrzyk J. (2013b). Vitamin D analogs enhance the anticancer activity of 5-fluorouracil in an in vivo mouse colon cancer model. BMC Cancer 13:294.
250. Milczarek M, Rosinska S, Psurski M, et al. (2013c). Combined colonic cancer treatment with vitamin D analogs and irinotecan or oxaliplatin. Anticancer Res 13:433-44.
251. Milczarek M, Filip-Psurska B, Swiętnicki W, et al. (2014). Vitamin D analogs combined with 5-fluorouracil in human HT-29 colon cancer treatment. Oncol Rep 32:491-504.
252. Mimori K, Tanaka Y, Yoshinaga K, et al. (2004). Clinical significance of the overexpression of the candidate oncogene CYP24 in esophageal cancer. Ann Oncol 15:236-41.
253. Mitschele T, Diesel B, Friedrich M, et al. (2004). Analysis of the vitamin D system in basal cell carcinomas (BCCs). Lab Invest 84:693-702.
254. Mittal MK, Myers JN, Misra S, et al. (2008). In vivo binding to and functional repression of the VDR gene promoter by SLUG in human breast cells. Biochem Biophys Res Commun 372:30-4.
255. Mohr SB, Gorham ED, Alcaraz JE, et al. (2011). Serum 25-hydroxyvitamin D and prevention of breast cancer: Pooled analysis. Anticancer Res 31:2939-48.
256. 2 (paricalcitol) exerts anticancer activity against HL-60 cells in vitro at clinically achievable concentrations. J Steroid Biochem Mol Biol 89-90:539-43.
257. Moreno J, Krishnan AV, Swami S, et al. (2005). Regulation of prostaglandin metabolism by calcitriol attenuates growth stimulation in prostate cancer cells. Cancer Res 65:7917-25.
258. Moreno J, Krishnan AV, Peehl DM, Feldman D. (2006). Mechanisms of vitamin D-mediated growth inhibition in prostate cancer cells: Inhibition of the prostaglandin pathway. Anticancer Res 26:2525-30.
259. Mori R, Xiong S, Wang Q, et al. (2009). Gene profiling and pathway analysis of neuroendocrine transdifferentiated prostate cancer cells. Prostate 69:12-23.
260. Morselli E, Galluzzi L, Kepp O, et al. (2009). Anti- and pro-tumor functions of autophagy. Biochim Biophys Acta 1793:1524-32.
261. 3 for prolongation of leukemic transformation-free survival in myelodysplastic syndromes. Am J Hematol 38:67-8.
262. Muindi JR, Nganga A, Engler KL, et al. (2007). CYP24 splicing variants are associated with different patterns of constitutive and calcitriolinducible CYP24 activity in human prostate cancer cell lines. J Steroid Biochem Mol Biol 103:334-7.
263. Muindi JR, Yu WD, Ma Y, et al. (2010). CYP24A1 inhibition enhances the antitumor activity of calcitriol. Endocrinology 151:4301-12.
264. 3 in human prostate cells. J Mol Endocrinol 47:209-18.
265. 3 induced growth inhibition of PC-3 prostate cancer cells requires an active transforming growth factor beta signaling pathway. Prostate 59:282-91.
266. Nagpal S, Na S, Rathnachalam R. (2005). Noncalcemic actions of vitamin D receptor ligands. Endocr Rev 26:662-87.
267. Nair-Shalliker V, Armstrong BK, Fenech M. (2012). Does vitamin D protect against DNA damage? Mutat Res 733:50-7
268. 3 inhibits metastasis and angiogenesis in lung cancer. Carcinogenesis 26:1044-54.
269. Nickerson T, Huynh H. (1999). Vitamin D analogue EB1089-induced prostate regression is associated with increased gene expression of insulin-like growth factor binding proteins. J Endocrinol 160:223-9.
270. Nishii Y, Okano T. (2001). History of the development of new vitamin D analogs: Studies on 22-oxacalcitriol (OCT) and 2beta-(3-hydroxypropoxy) calcitriol (ED-71). Steroids 66:137-46.
271. 3 and two synthetic analogues in three in vivo models of prostate cancer. BJU Int 90:607-16.
272. 3 for Japanese patients with metastatic renal cell carcinoma. Int J Urol 15:794-9.
273. Oh YS, Kim EJ, Schaffer BS, et al. (2001). Synthetic low-calcaemic vitamin D (3) analogues inhibit secretion of insulin-like growth factor II and stimulate production of insulin-like growth factor-binding protein-6 in conjunction with growth suppression of HT-29 colon cancer cells. Mol Cell Endocrinol 183:141-9.
274. 3 analogs: Large structure/function analysis and ability to induce antimicrobial peptide. Int J Cancer 134:207-17.
275. Okamoto R, Wakimoto N, Doan NB, et al. (2012). Inecalcitol, an analog of 1α, 25 (OH) (2) D (3) induces growth arrest of androgen-dependent prostate cancer cells. Int J Cancer 130:2464-73.
276. 3 with Julia olefination: High potency in induction of differentiation on HL-60 cells. J Org Chem 68:7407-15.
277. 3. Carcinogenesis 16:2091-7.
278. Pala V, Krogh V, Berrino F, et al. (2009). Meat, eggs, dairy products, and risk of breast cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Am J Clin Nutr 90:602-12.
279. Pálmer HG, González-Sancho JM, Espada J, et al. (2001). Vitamin D (3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling. J Cell Biol 154:369-87.
280. Pálmer HG, Larriba MJ, García JM, et al. (2004). The transcription factor SNAIL represses vitamin D receptor expression and responsiveness in human colon cancer. Nat Med 10:917-19.
281. 3 in human colon cancer cells. Cancer Res 63:7799-806.
282. Pan L, Matloob AF, Du J, et al. (2010). Vitamin D stimulates apoptosis in gastric cancer cells in synergy with trichostatin A/sodium butyrateinduced and 5-aza-20-deoxycytidine-induced PTEN upregulation. FEBS J 277:989-99.
283. 2 on gastric cancer cells and peritoneal metastasis model. J Korean Med Sci 27:1037-43.
284. 3 in primary cultures of human prostatic epithelial cells revealed by cDNA microarray analysis. J Steroid Biochem Mol Biol 92:131-41.
285. Pelczynska M, Switalska M, Maciejewska M, et al. (2006). Antiproliferative activity of vitamin D compounds in combination with cytostatics. Anticancer Res 26:2701-5.
286. Peña C, García JM, Silva J, et al. (2005). E-cadherin and vitamin D receptor regulation by SNAIL and ZEB1 in colon cancer: Clinicopathological correlations. Hum Mol Genet 14:3361-70.
287. Pendás-Franco N, González-Sancho JM, Suárez Y, et al. (2007). Vitamin D regulates the phenotype of human breast cancer cells. Differentiation 75:193-207.
288. Pendás-Franco N, Aguilera O, Pereira F, et al. (2008a). Vitamin D and Wnt/beta-catenin pathway in colon cancer: Role and regulation of DICKKOPF genes. Anticancer Res 28:2613-23.
289. 3. Oncogene 27:4467-77.
290. Peng L, Malloy PJ, Feldman D. (2004). Identification of a functional vitamin D response element in the human insulin-like growth factor binding protein-3 promoter. Mol Endocrinol 18:1109-19.
291. Peng L, Wang J, Malloy PJ, Feldman D. (2008). The role of insulin-like growth factor binding protein-3 in the growth inhibitory actions of androgens in LNCaP human prostate cancer cells. Int J Cancer 22:558-66.
292. Penna G, Fibbi B, Amuchastegui S, et al. (2009). The vitamin D receptor agonist elocalcitol inhibits IL-8-dependent benign prostatic hyperplasia stromal cell proliferation and inflammatory response by targeting the RhoA/Rho kinase and NF-kappaB pathways. Prostate 69:480-93.
293. Pereira F, Larriba MJ, Muñoz A. (2012). Vitamin D and colon cancer. Endocr Relat Cancer 19:51-71.
294. Pervin S, Hewison M, Braga M, et al. (2013). Down-regulation of vitamin D receptor in mammospheres: Implications for vitamin D resistance in breast cancer and potential for combination therapy. PLoS One 8:e53287.
295. Petrich A, Kahl B, Bailey H, et al. (2008). Phase II study of doxercalciferol for the treatment of myelodysplastic syndrome. Leuk Lymphoma 49:57-6.
296. Pilz S, Kienreich K, Tomaschitz A, et al. (2013). Vitamin D and cancer mortality: Systematic review of prospective epidemiological studies. Anticancer Agents Med Chem 13:107-17.
297. Pirianov G, Colston KW. (2001). Interactions of vitamin D analogue CB1093, TNFalpha and ceramide on breast cancer cell apoptosis. Mol Cell Endocrinol 172:69-78.
298. Plum LA, Fitzpatrick LA, Ma X, et al. (2006). 2MD, a new anabolic agent for osteoporosis treatment. Osteoporos Int 17:704-15.
299. Pommergaard HC, Burcharth J, Rosenberg J, Raskov H. (2013). Combination chemoprevention with diclofenac, calcipotriol and difluoromethylornithine inhibits development of non-melanoma skin cancer in mice. Anticancer Res 33:3033-9.
300. 3 synergistically down-regulate Akt and MDM2 leading to TGFb-1-dependent growth inhibition of breast cancer cells. J Pineal Res 50:150-8.
301. Reddy KK. (2013). Vitamin D level and basal cell carcinoma, squamous cell carcinoma, and melanoma risk. J Invest Dermatol 133:589-92.
302. Reichrath J, Rafi L, Rech M, et al. (2004). Analysis of the vitamin D system in cutaneous squamous cell carcinomas. J Cutan Pathol 31:224-31.
303. Ritter CS, Brown AJ. (2011). Suppression of PTH by the vitamin D analog eldecalcitol is modulated by its high affinity for the serum vitamin D-binding protein and resistance to metabolism. J Cell Biochem 112:1348-52.
304. Rollison DE, Cole AL, Tung KH, et al. (2012). Vitamin D intake, vitamin D receptor polymorphisms, and breast cancer risk among women living in the southwestern U. S. Breast Cancer Res Treat 132:683-91.
305. 3, gamma interferon, and control of proliferation of mycobacterium tuberculosis by human monocytes. Immunology 57:159-63.
306. Rose AA, Elser C, Ennis M, Goodwin PJ. (2013). Blood levels of vitamin D and early stage breast cancer prognosis: A systematic review and meta-analysis. Breast Cancer Res Treat 141:331-9.
307. Ross AC, Manson JE, Abrams SA, et al. (2011). The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: What clinicians need to know. J Clin Endocrinol Metab 96:53-8.
308. Rossi M, McLaughlin JK, Lagiou P, et al. (2009). Vitamin D intake and breast cancer risk: A case-control study in Italy. Ann Oncol 20:374-8.
309. 3 induction in myeloid leukemic cells. Mol Cell Biol 18:1911-18.
310. Roy R, Chun J, Powell SN. (2011). BRCA1 and BRCA2: Different roles in a common pathway of genome protection. Nat Rev Cancer 12:68-78.
311. Rozen F, Yang XF, Huynh H, Pollak M. (1997). Antiproliferative action of vitamin D-related compounds and insulin-like growth factorbinding protein 5 accumulation. J Natl Cancer Inst 89:652-6.
312. 3 analogs mediated by p27, Cdk2, cyclin E, and the retinoblastoma protein. Biochem Pharmacol 66:495-504.
313. Sahin M, Sahin E, Gumuslu S. (2009). Cyclooxygenase-2 in cancer and angiogenesis. Angiology 60:242-53.
314. Samuel S, Sitrin MD. (2008). Vitamin D's role in cell proliferation and differentiation. Nutr Rev 66:S116-24.
315. Sanford M, McCormack PL. (2011). Eldecalcitol: A review of its use in the treatment of osteoporosis. Drugs 10:1755-70.
316. Sakaki T, Yasuda K, Kittaka A, et al. (2014). CYP24A1 as a potential target for cancer therapy. Anticancer Agents Med Chem 14:97-108.
317. 3, retinoic acid and dexamethasone. Anticancer Drugs 4:201-8.
318. Schuster I. (2011). Cytochromes P450 are essential players in the vitamin D signaling system. Biochim Biophys Acta 1814:186-99.
319. Schwab M, Reynders V, Loitsch S, et al. (2007). Involvement of different nuclear hormone receptors in butyrate-mediated inhibition of inducible NF kappa B signalling. Mol Immunol 44:3625-32.
320. 2 (paricalcitol) in advanced, androgen-insensitive prostate cancer. Clin Cancer Res 11:8680-5.
321. 2 (paricalcitol) inhibits the proliferation of human pancreatic cancer cells in vitro and in vivo. Cancer Biol Ther 7:430-6.
322. Segersten U, Correa P, Hewison M, et al. (2002). 25-hydroxyvitamin D (3)-1alpha-hydroxylase expression in normal and pathological parathyroid glands. J Clin Endocrinol Metab 87:2967-72.
323. 2+ signaling in breast cancer. Anticancer Res 32:299-302.
324. 3 efficiently inhibits tumor growth in inoculated mice and primary histoculture of cholangiocarcinoma. Cancer 116:5535-43.
325. Shah S, Islam MN, Dakshanamurthy S, et al. (2006). The molecular basis of vitamin D receptor and beta-catenin crossregulation. Mol Cell 21:799-809.
326. Shanafelt TD, Drake MT, Maurer MJ, et al. (2011). Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia. Blood 3:1492-8.
327. Shin MH, Holmes MD, Hankinson SE, et al. (2002). Intake of dairy products, calcium, and vitamin D and risk of breast cancer. J Natl Cancer Inst 94:1301-11.
328. Singletary K, Milner J. (2008). Diet, autophagy, and cancer: A review. Cancer Epidemiol Biomarkers Prev 17:1596-610.
329. So JY, Lee HJ, Smolarek AK, et al. (2011). A novel Gemini vitamin D analog represses the expression of a stem cell marker CD44 in breast cancer. Mol Pharmacol 79:360-7.
330. So JY, Smolarek AK, Salerno DM, et al. (2013a). Targeting CD44-STAT3 signaling by Gemini vitamin D analog leads to inhibition of invasion in basal-like breast cancer. PLoS One 8:e54020.
331. So JY, Wahler JE, Yoon T, et al. (2013b). Oral administration of a gemini vitamin D analog, a synthetic triterpenoid and the combination prevents mammary tumorigenesis driven by ErbB2 overexpression. Cancer Prev Res (Phila) 6:959-70.
332. 3-dependent signal transduction by phosphorylating human retinoid X receptor alpha. J Clin Invest 103:1729-35.
333. Solomon JD, Heitzer MD, Liu TT, et al. (2014). VDR activity is differentially affected by hic-5 in prostate cancer and stromal cells. Mol Cancer Res 12:1166-80.
334. Spina CS, Ton L, Yao M, et al. (2007). Selective vitamin D receptor modulators and their effects on colorectal tumor growth. J Steroid Biochem Mol Biol 103:757-62.
335. 3 is accompanied by an increase in insulin-like growth factor binding protein-3. J Endocrinol 170:609-18.
336. Srinivasan M, Parwani AV, Hershberger PA, et al. (2011). Nuclear vitamin D receptor expression is associated with improved survival in non-small cell lung cancer. J Steroid Biochem 123:30-6.
337. 3 response by cancer-associated mutant p53. Cancer Cell 17:273-85.
338. Stewart LMV, Weigel NL. (2004). Vitamin D and prostate cancer. Exp Biol Med 229:4277-84.
339. Stio M, Martinesi M, Simoni A, et al. (2011). The novel vitamin D analog ZK191784 inhibits prostate cancer cell invasion. Anticancer Res 31:4091-8.
340. Stubbs JR, Idiculla A, Slusser J, et al. (2010). Cholecalciferol supplementation alters calcitriol-responsive monocyte proteins and decreases inflammatory cytokines in ESRD. J Am Soc Nephrol 21:353-61.
341. 3 analog EB 1089 enhances the antiproliferative and apoptotic effects of adriamycin in MCF-7 breast tumor cells. Breast Cancer Res Treat 63:1-10.
342. 3 analog, EB 1089, with ionizing radiation reduces tumor growth and induces apoptosis of MCF-7 breast tumor xenografts in nude mice. Clin Cancer Res 9:2350-6.
343. Suzuki Y, Ichiyama T, Ohsaki A, et al. (2009). Anti-inflammatory effect of 1alpha, 25-dihydroxyvitamin D (3) in human coronary arterial endothelial cells: Implication for the treatment of Kawasaki disease. J Steroid Biochem 113:134-8.
344. Swami S, Raghavachari N, Muller UR, et al. (2003). Vitamin D growth inhibition of breast cancer cells: Gene expression patterns assessed by cDNA microarray. Breast Cancer Res Treat 80:49-62.
345. Swami S, Krishnan AV, Feldman D. (2011). Vitamin D metabolism and action in the prostate: Implications for health and disease. Mol Cell Endocrinol 5:61-9.
346. Switalska M, Nasulewicz-Goldeman A, Opolska A, et al. (2012). The invitro antiproliferative effect of PRI-2191 and imatinib applied in combined treatment with cisplatin, idarubicin, or docetaxel on human leukemia cells. Anticancer Drugs 23:70-80.
347. 3 is an autonomus regulator of the transcriptional changes leading to a tolerogenic dendritic cell phenotype. J Immunol 182:2074-83.
348. 3 and calcium prevents bone mass loss in patients with advanced prostatic carcinoma after orchidectomy treated with complete androgenic blockade. Endokrynol Pol 56:225-32.
349. Tang JY, Fu T, Lau C, et al. (2012). Vitamin D in cutaneous carcinogenesis: Part II. J Am Acad Dermatol 67:817.e1-11, quiz 827-8.
350. Tang JY, Parimi N, Wu A, et al. (2010). Inverse association between serum 25 (OH) vitamin D levels and non-melanoma skin cancer in elderly men. Cancer Causes Control 21:387-91.
351. 3-based therapies. FASEB J 28:364-72.
352. Tavera-Mendoza L, Wang TT, Lallemant B, et al. (2006). Convergence of vitamin D and retinoic acid signalling at a common hormone response element. EMBO Rep 7:180-5.
353. Teegarden D, Donkin SS. (2009). Vitamin D: Emerging new roles in insulin sensitivity. Nutr Res Rev 22:82-92.
354. Thill M, Hoellen F, Becker S, et al. (2012). Expression of prostaglandinand vitamin D-metabolising enzymes in benign and malignant breast cells. Anticancer Res 32:367-72.
355. 3) and prostaglandin E2 (PGE2) serum level in ovarian cancer patients. J Steroid Biochem Mol Biol 121:387-90.
356. Thorne JL, Maguire O, Doig CL. (2011). Epigenetic control of a VDR-governed feed-forward loop that regulates p21 (waf1/cip1) expression and function in non-malignant prostate cells. Nucleic Acids Res 39:2045-56.
357. 3 responsiveness. Mol Cancer Res 5:967-80.
358. 3. Cancer Lett 247:122-9.
359. Ting HJ, Yasmin-Karim S, Yan SJ, et al. (2012). A positive feedback signaling loop between ATM and the vitamin D receptor is critical for cancer chemoprevention by vitamin D. Cancer Res 72:958-68.
360. 3 analog for the potential treatment of benign prostatic hyperplasia, overactive bladder and male infertility. Drugs 12:381-93.
361. Tosetti F, Ferrari N, De Flora S, Albini A. (2002). 'Angioprevention': Angiogenesis is a common and key target for cancer chemopreventive agents. FASEB J 16:2-14.
362. Tretli S, Hernes E, Berg JP, et al. (2009). Association between serum 25 (OH) D and death from prostate cancer. Br J Cancer 100:450-4.
363. Trouillas P, Honnorat J, Bret P, et al. (2001). Redifferentiation therapy in brain tumors: Long-lasting complete regression of glioblastomas and an anaplastic astrocytoma under long term 1-alpha-hydroxycholecalciferol. J Neurooncol 51:57-66.
364. Trump DL, Deeb KK, Johnson CS. (2010). Vitamin D: Considerations in the continued development as an agent for cancer prevention and therapy. Cancer J 16:1-9.
365. 3 inhibits transcriptional potential of nuclear factor kappa B in breast cancer cells. Mol Immunol 47:1728-38.
366. 3 on transforming growth factors in rectal mucosa of sporadic colorectal adenoma patients: A randomized controlled trial. Mol Carcinog. [Epub ahead of print]. doi:10.1002/mc.22096.
367. Urbschat A, Paulus P, Von Quernheim QF, et al. (2013). Vitamin D hydroxylases CYP2R1, CYP27B1 and CYP24A1 in renal cell carcinoma. Eur J Clin Invest 43:1282-90.
368. 3 derivatives. Anticancer Res 24:683-9.
369. Valko M, Rhodes CJ, Moncol J, Izakovic MM. (2006). Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact 160:1-40.
370. Valrance ME, Brunet AH, Welsh J. (2007). Vitamin D receptordependent inhibition of mammary tumor growth by EB1089 and ultraviolet radiation in vivo. Endocrinology 148:4887-94.
371. Van Den Bemd GJ, Chang GT. (2002). Vitamin D and vitamin D analogs in cancer treatment. Curr Drug Targets 3:85-94.
372. 3 enhance human osteoblast differentiation and mineralization. J Cell Biochem 99:922-35.
373. 2 inhibits growth of human neuroblastoma. J Neurooncol 85:255-62.
374. Vanoirbeek E, Krishnan A, Eelen G, et al. (2011). The anti-cancer and anti-inflammatory actions of 1, 25 (OH) D. Best Pract Res Clin Endocrinol Metab 25:593-604.
375. 3 analog, EB1089. Endocrinology 139:2102-10.
376. 3 on the cell cycle genes, cyclin D1, p21 and p27 in MCF-7 cells. Mol Cell Endocrinol 142:57-65.
377. 3 inhibit the growth of human breast cancer cells in vitro and in vivo. Cancer Res 60:2673-9.
378. Vuolo L, Di Somma C, Faggiano A, Colao A. (2012). Vitamin D and cancer. Front Endocrinol 3:58. doi:10.3389/fendo.2012.00058.
379. Wactawski-Wende J, Kotchen JM, Anderson GL, et al. (2006). Women's Health Initiative Investigators Calcium plus vitamin D supplementation and the risk of colorectal cancer. New Eng J Med 354:684-96.
380. Wahler J, So JY, Kim YC, et al. (2014). Inhibition of the transition of ductal carcinoma in situ to invasive ductal carcinoma by a Gemini vitamin D analog. Cancer Prev Res (Phila) 7:617-26.
381. Wang D, Dubois RN. (2010). Eicosanoids and cancer. Nat Rev Cancer 10:181-93.
382. 3 induces autophagy of human myeloid leukemia cells. J Biol Chem 12:25596-605.
383. 3 in HL60 cells. Cancer Res 56:264-7.
384. 3 is a direct inducer of antimicrobial peptide gene expression. J Immunol 173:2909-12.
385. 2/CARD15-defensin beta2 innate immune pathway defective in Crohn disease. J Biol Chem 285:2227-31.
386. Wang X, Chen W, Singh N, et al. (2010b). Effects of potential calcium sensing receptor inducers on promoting chemosensitivity of human colon carcinoma cells. Int J Oncol 36:1573-80.
387. Wang Y, Zhu J, De Luca HF. (2012). Where is the vitamin D receptor? Arch Biochem Biophys 523:123-33.
388. 3 is associated with increased mitochondrial MCL-1 and RAF-1 proteins and reduced release of cytochrome c. Exp Cell Res 235:210-17.
389. Welsh J. (2012). Cellular and molecular effects of vitamin D on carcinogenesis. Arch Biochem Biophys 523:107-14.
390. 3 (PRI2191). Steroids 69:629-35.
391. 2 and chemotherapeutic agents on human breast and prostate cancer cell lines. Anticancer Res 24:2905-12.
392. 3 stimulates activin A production to finetune osteoblast-induced mineralization. J Cell Physiol 228:2167-74.
393. Woolcott CG, Wilkens LR, Nomura AM, et al. (2010). Plasma 25-hydroxyvitamin D levels and the risk of colorectal cancer: The multiethnic cohort study. Cancer Epidemiol Biomarkers Prev 19:130-4.
394. 3 and its analogues. J Biol Chem 273:7749-56.
395. Wu RY, Zhang Y, Feng XH, Derynck R. (1997a). Homomeric and heteromeric interactions are required for signaling activity and functional cooperativity of Smad-3 and -4. Mol Cell Biol 17:2521-8.
396. Wu S, Sun J. (2011). Vitamin D, vitamin D receptor, and macroautophagy in inflammation and infection. Discov Med 11:325-35.
397. 3 increases transforming growth factor and transforming growth factor receptor type I and II synthesis in human bone cells. Biochem Biophys Res Commun 239:734-9.
398. Xiao W, Hodge DR, Wang L, et al. (2004). Co-operative functions between nuclear factors NFκB and CCAT/enhancer-binding protein-b (C/EBP-b) regulate the IL-6 promoter in autocrine human prostate cancer cells. Prostate 61:354-70.
399. Xu H, Posner GH, Stevenson M, Campbell FC. (2010). Apc (MIN) modulation of vitamin D secosteroid growth control. Carcinogenesis 31:1434-41.
400. Xu J, Li W, Ma J, et al. (2013). Vitamin D pivotal nutraceutical in the regulation of cancer metastasis and angiogenesis. Curr Med Chem 20:4109-20.
401. Yanagisawa J, Yanagi Y, Masuhiro Y, et al. (1999). Convergence of transforming growth factor-beta and vitamin D signaling pathways on SMAD transcriptional coactivators. Science 26:1317-21.
402. Yang ES, Burnstein KL. (2003). Vitamin D inhibits G1 to S progression in LNCaP prostate cancer cells through p27Kip1 stabilization and Cdk2 mislocalization to the cytoplasm. J Biol Chem 278:46862-8.
403. 3 analog-induced growth inhibition in breast cells. J Cell Physiol 188:383-93.
404. Yao S, Ambrosone CB. (2013). Associations between vitamin D deficiency and risk of aggressive breast cancer in African-American women. J Steroid Biochem Mol Biol 136:337-41.
405. 3 in head and neck cancer. Cancers (Basel) 5:1072-85.
406. 3 inhibits growth of the breast cancer cell line MCF-7 and downregulates cytochrome P4501B1 through the COX-2/PGE2 pathway. Oncol Rep 28:2131-7.
407. Zehnder D, Bland R, Chana RS, et al. (2002). Synthesis of 1, 25-dihydroxyvitamin D (3) by human endothelial cells is regulated by inflammatory cytokines: A novel autocrine determinant of vascular cell adhesion. J Am Soc Nephrol 13:621-9.
408. Zhang J, Zhang H, Zhang X, Yu Z. (2013). Synergistic effect of retinoic acid and vitamin D analog EB1089-induced apoptosis of hepatocellular cancer cells. Cytotechnology 65:457-65.
409. 3 revealed by microarray analysis. J Biol Chem 280:35458-68.
410. Zhang Y, Guo Q, Zhang Z, et al. (2014). VDR status arbitrates the prometastatic effects of tumor-associated macrophages. Mol Cancer Res 12:1181-91.
411. Zhang Z, Kovalenko P, Cui M, et al. (2010). Constitutive activation of the mitogen-activated protein kinase pathway impairs vitamin D signaling in human prostate epithelial cells. J Cell Physiol 224:433-42.
412. 3 actions in LNCaP human prostate cancer cells are androgen-dependent. Endocrinology 138:3290-8.
413. Zhou S, Le Boff MS, Glowacki J. (2010). Vitamin D metabolism and action in human bone marrow stromal cells. Endocrinology 151:14-22.
414. 3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation. Endocrinology 139:1197-207.
415. Zhuang SH, Schwartz GG, Cameron D, Burnstein KL. (1997). Vitamin D receptor content and transcriptional activity do not fully predict antiproliferative effects of vitamin D in human prostate cancer cell lines. Mol Cell Endocrinol 126:83-90.